Linezolid is recommended for the treatment of rifampin-resistant tuberculosis (TB), but its role in rifampin-susceptible TB (RS-TB) is less understood. In 45 RS-TB patients treated with linezolid, 8 stopped due to adverse events, most commonly cytopenias. Further research is needed on linezolid efficacy, dosing, and adverse event management in RS-TB.
No takes yet. Share an insight, caveat, or question.
Louie et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: